There are 449 resources available
Role of TROP-2 in NSCLC
Presenter: David Planchard
Session: Clinical Care Options, LLC - TROP-2–targeted ADCs for NSCLC: Integrating a new therapeutic option
Resources:
Webcast
Tissue and liquid-based next-generation sequencing diagnostics for patients with advanced NSCLC: Platforms, timings and issues with tissues
Presenter: Antonio Calles Blanco
Session: ESMO Colloquium supported by Eli Lilly and Company - Optimising molecular diagnosis and precision therapy in patients with advanced NSCLC harbouring rare oncogenic translocations
Resources:
Slides
Webcast
Latest therapeutic advancements in targeting TROP-2 in NSCLC
Presenter: Helena A. Yu
Session: Clinical Care Options, LLC - TROP-2–targeted ADCs for NSCLC: Integrating a new therapeutic option
Resources:
Webcast
Molecular Reports in advanced NSCLC: How to optimise report structure, molecular tumour board input and actionability
Presenter: Ales Ryska
Session: ESMO Colloquium supported by Eli Lilly and Company - Optimising molecular diagnosis and precision therapy in patients with advanced NSCLC harbouring rare oncogenic translocations
Resources:
Slides
Webcast
Contemplating the future role of targeting TROP-2 in NSCLC
Presenter: Luis Paz-Ares
Session: Clinical Care Options, LLC - TROP-2–targeted ADCs for NSCLC: Integrating a new therapeutic option
Resources:
Webcast
Optimal therapeutic regimens for advanced NSCLC patients with rare oncogenic translocations (beyond ALK) and insights on resistance upon retesting
Presenter: Zofia Piotrowska
Session: ESMO Colloquium supported by Eli Lilly and Company - Optimising molecular diagnosis and precision therapy in patients with advanced NSCLC harbouring rare oncogenic translocations
Resources:
Slides
Webcast
Panel discussion with audience question and answer session
Presenter: Helena A. Yu
Session: Clinical Care Options, LLC - TROP-2–targeted ADCs for NSCLC: Integrating a new therapeutic option
Resources:
Webcast
Q&A and discussion
Session: ESMO Colloquium supported by Eli Lilly and Company - Optimising molecular diagnosis and precision therapy in patients with advanced NSCLC harbouring rare oncogenic translocations
Resources:
Webcast
Concluding remarks
Presenter: Antonio Calles Blanco
Session: ESMO Colloquium supported by Eli Lilly and Company - Optimising molecular diagnosis and precision therapy in patients with advanced NSCLC harbouring rare oncogenic translocations
Resources:
Webcast
LBA2 - Clinical outcomes with perioperative nivolumab (NIVO) in patients (PTS) with resectable NSCLC from the phase III CheckMate 77T study
Presenter: Mark Awad
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast